In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed...
In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD)...
On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the type II RAF inhibitor tovorafenib (Ojemda) for patients 6 months of age...
On April 23, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older...
Recently, the U.S. Food and Drug Administration (FDA) approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative...
In a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center involving more than 3,000 women treated for breast cancer at the height of the COVID-19 pandemic in New York City, only 64 patients, or 2% of the total study population, contracted the virus. Of this group, 10 died ...
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
The Lymphoseek (technetium Tc 99m tilmanocept) injection—a radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies—has been approved for pediatric use by the U.S. Food and Drug Administration (FDA). "This new indication opens the door ...
Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, were presented by Grossmann et al...
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...